Results 271 to 280 of about 96,571 (302)
Some of the next articles are maybe not open access.
Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose
Radiologic Clinics of North America, 2004Twenty-eight years after its inception, 2-[18F]FDG- is still the most widely used radiopharmaceutical for PET studies, but numerous more specific radiotracers have been developed and applied in neuroscience and oncology. The advances in radiotracer chemistry, especially the nucleophilic substitution reaction, have played the pivotal role in ...
Chyng-Yann, Shiue, Michael J, Welch
openaire +2 more sources
Brain 18F-Fluorodeoxyglucose (FDG) PET
2018In the last decades, 18F-FDG PET imaging has been extensively used to study glucose brain metabolism [1]. Glucose uptake distribution in the brain is mainly driven by basal neuronal activity and represents general neuronal integrity [2, 3]. The highest values of glucose consumption are found in the basal ganglia, the thalami, and the occipital polar ...
Stefano Fanti +3 more
openaire +1 more source
Normal variants in [18F]-fluorodeoxyglucose PET imaging
Radiologic Clinics of North America, 2004The number of fluorodeoxyglucose PET applications is increasing. In the process of reading fluorodeoxyglucose-PET scans, nuclear medicine physicians encounter a wide variety of normal findings, which must be recognized to determine the best management for patients.
Ghassan, El-Haddad +4 more
openaire +2 more sources
PET clinics, 2022
PET/computed tomography (CT) with fluorodeoxyglucose and nonfluorodeoxyglucose PET tracers has established itself in the management of malignant disorders. Its role in the assessment of nonmalignant conditions, such as infectious and noninfectious inflammatory diseases and other benign conditions, has emerged independently and alongside its role being ...
Vandana Kumar, Dhingra +3 more
openaire +1 more source
PET/computed tomography (CT) with fluorodeoxyglucose and nonfluorodeoxyglucose PET tracers has established itself in the management of malignant disorders. Its role in the assessment of nonmalignant conditions, such as infectious and noninfectious inflammatory diseases and other benign conditions, has emerged independently and alongside its role being ...
Vandana Kumar, Dhingra +3 more
openaire +1 more source
Fluorodeoxyglucose-PET in Breast Cancer
2006Similar to the previously discussed approved applications in oncology, FDGPET in breast cancer has demonstrated superior diagnostic accuracy compared with conventional anatomic imaging for the detection of distant metastases. This increased accuracy in lesion detection has translated into improved staging, especially in cases with a high clinical ...
Bennett B. Chin +2 more
openaire +1 more source
Lung Neoplasms with Low F18-Fluorodeoxyglucose Avidity
PET Clinics, 2018Some malignant lung neoplasms may demonstrate low or absent uptake on F18-fluorodeoxyglucose (FDG) PET/computed tomography. Pathologic type and clinical stage are independent factors associated with FDG avidity. Among lung malignancies with low FDG avidity, adenocarcinoma in situ and carcinoid are the most common.
openaire +2 more sources
Cerebrovascular Disease: Use of Fluorodeoxyglucose
Seminars in Neurology, 1989K, Herholz, W D, Heiss
openaire +2 more sources
Quantification in clinical fluorodeoxyglucose positron emission tomography
Nuclear Medicine Communications, 2004Positron emission tomography (PET) is increasingly used clinically to provide functional information on disease processes, especially in oncology using the glucose analogue 2-[18F]fluoro-2-deoxy-D-glucose (F-FDG). In the clinical setting it has become standard practice to use simplified imaging protocols compared to the often complex methods developed ...
openaire +2 more sources